用于T细胞治疗的瘤特异性抗原传递通过pH敏感合物传递
Annali M Yurkevicz1,2, Yanfeng Liu1, Samuel G Katz3
1Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut.
Molecular cancer therapeutics
|October 9, 2024
概括
一种新的低pH插入 (pHLIP) 输送系统成功地用人工抗原 (SIINFEKL) 向瘤细胞. 这种方法激活T细胞并抑制瘤生长,为癌症免疫治疗提供了一种新的策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 生物技术是生物技术.
背景情况:
- 鉴定用于癌症治疗的瘤特异性抗原是困难的,因为癌症和健康组织之间存在相似之处.
- 低pH插入 (pHLIP) 可以准酸性瘤微环境,提供选择性输送方法.
研究的目的:
- 开发和评估一种pHLIP-联,用于针对性地将人工抗原传递给瘤细胞.
- 评估这种结合物在激活抗瘤免疫反应中的疗效,在体外和体内.
主要方法:
- 结合pHLIP与SIINFEKL (一个卵片段) 的结合.
- 使用黑色素瘤细胞和SIINFEKL特异性T细胞 (OT1) 进行体外研究,以评估T细胞激活.
- 在携带瘤的小鼠体内研究,以评估T细胞的招募和瘤生长抑制.
- 利用光标记的结构来选择性传递跟踪和siRNA/shRNA敲除,以调查MHC类I途径的作用.
主要成果:
- 确认了pHLIP-SIINFEKL对瘤细胞的选择性体外和体内输送.
- 在pHLIP-SIINFEKL治疗诱导了OT1T细胞激活和效应器功能在体外.
- 在pHLIP-SIINFEKL介导的T细胞识别中,瘤细胞中的MHC I类通路完整性至关重要.
- 在体内,pHLIP-SIINFEKL治疗导致OT1T细胞的招募和显著的瘤生长抑制.
结论:
- 像SIINFEKL这样的人工抗原的pHLIP介导的输送是癌症免疫治疗的可行策略.
- 这种方法使得有针对性的免疫细胞激活和瘤生长抑制.
- pHLIP平台为开发基于细胞的新型癌症疗法提供了一个有前途的方法.
相关概念视频
Tumor Immunotherapy
488
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
488
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


